Your browser doesn't support javascript.
loading
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.
Pulczynski, Elisa Jacobsen; Simonsen, Mikkel Runason; Kuittinen, Outi; Fagerli, Unn-Merete; Erlanson, Martin; Fluge, Øystein; Leppä, Sirpa; Østenstad, Bjørn; Fosså, Alexander; Eriksson, Mikael; El-Galaly, Tarec; Kuitunen, Hanne; Papworth, Karin; Ljungqvist, Maria; Pedersen, Martin B; Pollari, Marjukka.
Affiliation
  • Pulczynski EJ; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark; Department of Haematology, Region Hospital Goedstrup, Herning.
  • Simonsen MR; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Mathematical Sciences, Aalborg University, Aalborg.
  • Kuittinen O; Department of Oncology, Kuopio University Hospital Cancer Center, Kuopio, Finland; Faculty of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio.
  • Fagerli UM; Department of Oncology, St Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of science and technology (NTNU), Trondheim, Norway.
  • Erlanson M; Department of Radiation Sciences, Umeå University, Umeå, Sweden.
  • Fluge Ø; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
  • Leppä S; Research Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
  • Østenstad B; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Fosså A; Department of Oncology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway.
  • Eriksson M; Department of Oncology, Skane University Hospital, Lund, Sweden; Medical Oncology, Lund University, Lund, Sweden.
  • El-Galaly T; Department of Hematology, Aalborg University Hospital, Aalborg.
  • Kuitunen H; Cancer Centre, Oulu University Hospital, Oulu.
  • Papworth K; Department of Radiation Sciences, Umeå University, Umeå, Sweden.
  • Ljungqvist M; Department of Clinical Science and Education, Södersjukhuste, Karolinska Insitutet, Stockholm, Sweden; Haematology Centre, Karolinska University Hospital, Stockholm, Sweden.
  • Pedersen MB; Department of Haematology, Aarhus University Hospital, Aarhus.
  • Pollari M; Research Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere. marjukka.pollari@pirha.fi.
Haematologica ; 109(7): 2359-2363, 2024 Jul 01.
Article in En | MEDLINE | ID: mdl-38546689
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Central Nervous System Neoplasms / Temozolomide Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Haematologica Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Central Nervous System Neoplasms / Temozolomide Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Haematologica Year: 2024 Document type: Article